Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning

Archives of Medical Science

Volumn 13, Issue 2, 2017, Pages 448-458

  Gedik, Nilguen ^a   Maciel, Leonardo ^a,b   Schulte, Christiane ^a   Skyschally, Andreas ^a   Heusch, Gerd ^a   Kleinbongard, Petra ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cardioprotection; Humoral factor; Mitochondria; Remote ischemic preconditioning

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE PRESSURE; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; MITOCHONDRIAL RESPIRATION; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PIG; RAT; REMOTE ISCHEMIC PRECONDITIONING;

EID: 85013101830     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2016.61789     Document Type: Article

References (72)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
2. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon DM. Remote ischemic conditioning. J Am Coll Cardiol 2015; 65: 177-95.
3. Davies WR, Brown AJ, Watson W, et al. Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: The CRISP stent trial long-term follow-up. Circ Cardiovasc Interv 2013; 6: 246-51.
4. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomized controlled trial. Lancet 2007; 370: 575-9.
5. Thielmann M, Kottenberg E, Kleinbongard P, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: A single-centre randomised, double-blind, controlled trial. Lancet 2013; 382: 597-604.
6. Candilio L, Malik A, Ariti C, et al. Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: A randomised controlled clinical trial. Heart 2015; 10: 185-92.
7. Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: A randomised trial. Lancet 2010; 375: 727-34.
8. Eitel I, Stiermaier T, Rommel KP, et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: The randomized LIPSIA CONDITIONING trial. Eur Heart J 2015; 36: 3049-57.
9. Yellon DM, Ackbarkhan AK, Balgobin V, et al. Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis. J Am Coll Cardiol 2015; 65: 2764-5.
10. White SK, Frohlich GM, Sado DM, et al. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol Cardiovasc Interv 2015; 8: 178-88.
11. Sloth AD, Schmidt MR, Munk K, et al. Improved longterm clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. Eur Heart J 2014; 35: 168-75.
12. Hausenloy DJ, Candilio L, Evans R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 2015; 373: 1408-17.
13. Meybohm P, Bein B, Brosteanu O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 2015; 373: 1397-407.
14. Heusch G, Gersh BJ. ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not! Eur Heart J 2015; 37: 200-1.
15. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge. Eur Heart J 2016; doi:10.1093/eurheartj/ehw224.
16. Shimizu M, Tropak M, Diaz RJ, et al. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond) 2009; 117: 191-200.
17. Dickson EW, Lorbar M, Porcaro WA, et al. Rabbit heart can be "preconditioned" via transfer of coronary effluent. Am J Physiol 1999; 277: H2451-7.
18. Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G. Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. Circ Res 2015; 117: 279-88.
19. Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res 2014; 114: 1601-10.
20. Jensen RV, Stottrup NB, Kristiansen SB, Bøtker HE. Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res Cardiol 2012; 107: 285.
21. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118: 1915-9.
22. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-and remote conditioning. Circ Res 2015; 116: 674-99.
23. Cellier L, Tamareille S, Kalakech H, et al. Remote ischemic conditioning influences mitochondrial dynamics. Shock 2016; 45: 192-7.
24. Cao Y, Zhang SZ, Zhao SQ, Bruce IC. The mitochondrial Ca(2+)-activated K(+) channel contributes to cardioprotection by limb remote ischemic preconditioning in rat. Life Sci 2011; 88: 1026-30.
25. Ferko M, Kancirova I, Jasova M, et al. Remote ischemic preconditioning of the heart: protective responses in functional and biophysical properties of cardiac mitochondria. Physiol Res 2014; 63 Suppl 4: S469-78.
26. Slagsvold KH, Moreira JB, Rognmo O, et al. Remote ischemic preconditioning preserves mitochondrial function and activates pro-survival protein kinase Akt in the left ventricle during cardiac surgery: A randomized trial. Int J Cardiol 2014; 177: 409-17.
27. Slagsvold KH, Rognmo O, Hoydal M, Wisloff U, Wahba A. Remote ischemic preconditioning preserves mitochondrial function and influences myocardial microRNA expression in atrial myocardium during coronary bypass surgery. Circ Res 2014; 114: 851-9.
28. Wang L, Oka N, Tropak M, et al. Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest. J Thorac Cardiovasc Surg 2008; 136: 335-42.
29. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: The holy grail of cardioprotection. Basic Res Cardiol 2010; 105: 151-4.
30. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995; 307: 93-8.
31. Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 2008; 103: 464-71.
32. Skyschally A, Gres P, Hoffmann S, et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007; 100: 140-6.
33. Heusch P, Skyschally A, Leineweber K, Haude M, Erbel R, Heusch G. The interaction of coronary microembolization and ischemic preconditioning: A third window of cardioprotection through TNF-alpha. Arch Med Sci 2007; 3: 83-92.
34. Kleinbongard P, Schulz R, Heusch G. TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart FailRev 2011; 16: 49-69.
35. Bayne K. Revised guide for the care and use of laboratory animals available. American Physiological Society. Physiologist 1996; 39: 199, 208-11.
36. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNFalpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34: 509-18.
37. Kleinbongard P, Gedik N, Witting P, Freedman B, Klocker N, Heusch G. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol 2015; 172: 4380-90.
38. Gedik N, Heusch G, Skyschally A. Infarct size reduction by cyclosporine A at reperfusion involves inhibition of the mitochondrial permeability transition pore but does not improve mitochondrial respiration. Arch Med Sci 2013; 9: 968-75.
39. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of cyclophilin D. J Biol Chem 2005; 280: 18558-61.
40. Argaud L, Gateau-Roesch O, Chalabreysse L, et al. Preconditioning delays Ca2+-induced mitochondrial permeability transition. Cardiovasc Res 2004; 61: 115-22.
41. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007; 1767: 1007-31.
42. Lacerda L, Somers S, Opie LH, Lecour S. Ischemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009; 84: 201-8.
43. Lecour S, James RW. When are pro-inflammatory cytokines SAFE in heart failure? Eur Heart J 2011; 32: 680-5.
44. Kimura H, Shintani-Ishida K, Nakajima M, Liu S, Matsumoto K, Yoshida K. Ischemic preconditioning or p38 MAP kinase inhibition attenuates myocardial TNF-alpha production and mitochondria damage in brief myocardial ischemia. Life Sci 2006; 78: 1901-10.
45. Meldrum DR, Dinarello CA, Shames BD, et al. Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production. Potential ultimate effector mechanism of preconditioning. Circulation 1998; 98: II-214-9.
46. Belosjorow S, Schulz R, Dörge H, Schade FU, Heusch G. Endotoxin and ischemic preconditioning: TNF-alpha concentration and myocardial infarct development in rabbits. Am J Physiol Heart Circ Physiol 1999; 277: H2470-5.
47. Zhang JQ, Wang Q, Xue FS, et al. Ischemic preconditioning produces more powerful anti-inflammatory and cardioprotective effects than limb remote ischemic postconditioning in rats with myocardial ischemia-reperfusion injury. Chin Med J (Engl) 2013; 126: 3949-55.
48. Lecour S, Suleman N, Deuchar GA, et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005; 112: 3911-8.
49. Smith RM, Suleman N, McCarthy J, Sack MN. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNF-alpha gene. Cardiovasc Res 2002; 55: 553-60.
50. Gao Q, Zhang SZ, Cao CM, Bruce IC, Xia Q. The mitochondrial permeability transition pore and the Ca2+-activated K+ channel contribute to the cardioprotection conferred by tumor necrosis factor-alpha. Cytokine 2005; 32: 199-205.
51. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res 2013; 113: 709-24.
52. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/ reperfusion. Circ Res 2011; 109: 1302-8.
53. Yang S, Li H, Tang L, et al. Apelin-13 protects the heart against ischemia-reperfusion injury through the RISK-GSK-3beta-mPTP pathway. Arch Med Sci 2015; 11: 1065-73.
54. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010; 24: 85-7.
55. Argaud L, Gateau-Roesch O, Muntean D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005; 38: 367-74.
56. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. New Engl J Med 2008; 359: 473-81.
57. Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015; 373: 1021-103.
58. Ottani F, Latini R, Staszewsky L, et al. Cyclosporine A in reperfused myocardial infarction. The multicenter, contolled, open-label CYCLE Trial. J Am Coll Cardiol 2016; 67: 365-74.
59. Heusch G. CIRCUS - a kiss of death for cardioprotection? Cardiovasc Res 2015; 108: 215-6.
60. Kerr PM, Suleiman MS, Halestrap AP. Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate. Am J Physiol Heart Circ Physiol 1999; 276: H496-502.
61. Leung CH, Wang L, Nielsen JM, et al. Remote cardioprotection by transfer of coronary effluent from ischemic preconditioned rabbit heart preserves mitochondrial integrity and function via adenosine receptor activation. Cardiovasc Drugs Ther 2014; 28: 7-17.
62. Watts JA, Maiorano PC. Trace amounts of albumin protect against ischemia and reperfusion injury in isolated rat hearts. J Mol Cell Cardiol 1999; 31: 1653-62.
63. Burley DS, Hamid SA, Baxter GF. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart FailRev 2007; 12: 279-91.
64. Kruse R, Essen-Gustavsson B, Fossum C, Jensen-Waern M. Blood concentrations of the cytokines IL-1beta, IL-6, IL-10, TNF-alpha and IFN-gamma during experimentally induced swine dysentery. Acta Vet Scand 2008; 50: 32.
65. Webel DM, Finck BN, Baker DH, Johnson RW. Time course of increased plasma cytokines, cortisol, and urea nitrogen in pigs following intraperitoneal injection of lipopolysaccharide. J Animal Sci 1997; 75: 1514-20.
66. Xi S, Yin W, Wang Z, et al. A minipig model of high-fat/ high-sucrose diet-induced diabetes and atherosclerosis. Int J Exp Pathol 2004; 85: 223-31.
67. Ohta M, Tarnawski AS, Itani R, et al. Tumor necrosis factor alpha regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats. Hepatology 1998; 27: 906-13.
68. Darwish SF, El-Bakly WM, Arafa HM, El-Demerdash E. Targeting TNF-alpha and NF-kappaB activation by bee venom: role in suppressing adjuvant induced arthritis and methotrexate hepatotoxicity in rats. PLoS One 2013; 8: e79284.
69. Bosetti F, Baracca A, Lenaz G, Solaini G. Increased state 4 mitochondrial respiration and swelling in early post-ischemic reperfusion of rat heart. FEBS Lett 2004; 563: 161-4.
70. Lesnefsky EJ, Slabe TJ, Stoll MS, Minkler PE, Hoppel CL. Myocardial ischemia selectively depletes cardiolipin in rabbit heart subsarcolemmal mitochondria. Am J Physiol Heart Circ Physiol 2001; 280: H2770-8.
71. Holmuhamedov EL, Oberlin A, Short K, Terzic A, Jahangir A. Cardiac subsarcolemmal and interfibrillar mitochondria display distinct responsiveness to protection by diazoxide. PLoS One 2012; 7: e44667.
72. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/ reperfusion. Basic Res Cardiol 2010; 105: 771-85.